NeuroPace to Host Investor Day on January 28th in New York City

NPCE 12.12.2024

Full Press ReleaseSEC FilingsOur NPCE Tweets

About Gravity Analytica

Recent News

  • 01.28.2025 - January 28, 2025 9:00 AM EST - January 28, 2025 12:00 PM EST : NeuroPace In-Person Investor Day
  • 01.16.2025 - 43rd Annual JP Morgan Healthcare Conference
  • 01.08.2025 - NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

Recent Filings

  • 01.15.2025 - 8-K Current report
  • 01.08.2025 - 3 Initial statement of beneficial ownership of securities
  • 01.08.2025 - 4 Statement of changes in beneficial ownership of securities

MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will host an Investor Day from 9:00 a.m. – 12:00 p.m. ET on Tuesday, January 28, 2025 in New York City.

The Investor Day will provide an update on NeuroPace’s vision for its unique RNS technology and will highlight the Company’s plans including presentations from management discussing NeuroPace’s recent results, future plans, and market, product and clinical development strategies for the RNS System. The Company will also host guest speakers, including clinical key opinion leaders and an RNS patient who will provide their personal experience with the RNS System and its impact on their epilepsy.

Use the link below to register for the event:https://lifescievents.com/event/neuropace/

About NeuroPace, Inc.Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:Jeremy FefferManaging DirectorLifeSci Advisorsjfeffer@lifesciadvisors.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com